WE.SPEED.
We are delighted to share one of the most recent achievements at ARENSIA! Three ARENSIA clinics in Romania, Moldova, and Georgia have just completed the randomization of 30 patients with mild to moderate ulcerative colitis within a timeframe of 10 months, testing a novel orally active small molecule in a Phase IIA trial.
The trial design includes tight patient inclusion/exclusion criteria involving complex procedures such as endoscopies with biopsy collection, overnight stays, and an intensive PK/PD schedule.
Gastrointestinal research, particularly in the context of ulcerative colitis, continues to be a prominent focus across all ARENSIA clinics, with a rising trend.
We take pride in providing our patients early access to innovative therapies during drug development and in enabling our Sponsor to carry out the entire project with exceptional quality and cost efficiency. Unlike the industry norm, which involves numerous typical clinical trial sites, the Sponsor’s strategic use of three ARENSIA research-dedicated clinics proved both time-saving and efficient, completing trial enrollment two months ahead of the agreed schedule!
This achievement is a testament to the fantastic teamwork, and heartfelt gratitude goes to everyone involved in advancing this exciting science—patients, health authorities, ARENSIA investigator teams, the Sponsor, and the lead CRO!
25.10.2023